There are currently 59 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
NCT05783596
Recruiting
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Glofitamab (a type of immunotherapy) * Obinutuzumab (a type of immunotherapy)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +3 locations
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Register for Updates
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
NCT05281809
Recruiting
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
01/10/2025
Locations: AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphocytic Leukemia, Transformed Lymphoma
Register for Updates
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
NCT05410418
Recruiting
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin in order to see how well it works in patients with untreated follicular lymphoma. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead. Polatuzumab vedotin is an ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Lymphoma, Follicular, Follicular Lymphoma
Register for Updates
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT04594642
Recruiting
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
01/07/2025
Locations: Research Site, Tampa, Florida +26 locations
Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Register for Updates
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
NCT06043323
Recruiting
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Follicular Lymphoma
Register for Updates
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
NCT05551936
Recruiting
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendamustine 90 mg/m2 IV on days 1 and 2 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up to three cycles. Following this, patients will receive tazemetostat twice daily on days 1-28 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Northwestern University, Chicago, Illinois +4 locations
Conditions: Follicular Lymphoma
Register for Updates
Epcoritamab in Patients with Follicular Lymphoma Not Accomplishing a CR with Upfront Chemoimmunotherapy
NCT06510361
Recruiting
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Register for Updates
Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06550141
Recruiting
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
Register for Updates
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT04669171
Recruiting
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +11 locations
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265
Recruiting
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado
Conditions: B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, HGBL with MYC and BCL2 And/or BCL6 Rearrangements, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, Non-hodgkin Lymphoma,B Cell, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Epstein-Barr Virus Positive DLBCL, Nos, Follicular Lymphoma Grade 3B, DLBCL (Diffuse Large B-Cell Lymphoma) Associated with Chronic Inflammation, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma Grade 3, Marginal Zone Splenic Lymphoma, DLBCL
Register for Updates
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636
Recruiting
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/01/2024
Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
Register for Updates
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363
Recruiting
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: UC Irvine Health, Orange, California +8 locations
Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Register for Updates